Methods and compositions for RNA-guided treatment of HIV infection
US11298411B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2018 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | Dec 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/21
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a subject having a retroviral infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the retrovirus, and eradicating the retroviral infection. A method of immunizing a subject at risk of retroviral infection, by administering a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of a retrovirus to the subject, and preventing retroviral infection in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.